OUR TEAM

LEADERSHIP

Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW

Cameron Durrant, MD, DRCOG, MRCGP, MBA, FLSW

Chairman & CEO

​• Serial biotech experience as CEO, CFO, Chair, Exec Chair
• Merck, GSK, Pharmacia, J+J
• Launched 5 blockbusters during career, including antivirals

Dale Chappell, MD, MBA

Dale Chappell, MD, MBA

Chief Scientific Officer

• Founder, Black Horse Capital Advisors
• Decades of biotechnology investment experience
• HHMI Fellow, National Cancer Institute, Rosenberg Lab
• Multiple publications in T-cell therapy, GM-CSF and immunology pathways

Timothy E. Morris

Timothy E. Morris

Chief Operating and Financial Officer

• Over 36 years of professional finance and accounting experience
• Over 22 years as CFO with public biotechnology companies (IOVA, ACRX, VVUS, QCOR)
• Raised over $2 Bn in equity and convertible securities for seven companies, completed four offerings for IOVA with over $1 Bn in proceeds
• Oversaw increase in market cap of Iovance Biotherapeutics from $550 Mn to $4.2 Bn (7x increase)
• Extensive deal experience with over 75 transactions and combined value in excess of $4 Bn

Adrian Kilcoyne, MD, MBA, MPH, MFPM, MRCGP

Adrian Kilcoyne, MD, MBA, MPH, MFPM, MRCGP

Chief Medical Officer

• Leadership experience across Medical Affairs, Evidence Generation and R&D
• Over 15 years of clinical experience (AstraZeneca, Celgene, Sanofi, Roche, Baxter, Eli Lilly)
• Expertise in COVID-19 and CAR-T
• Directed numerous projects spanning oncology and lymphoma programs

Edward P. Jordan, MBA

Edward P. Jordan, MBA

Chief Commercial Officer

• Over 20 years experience building and leading commercial organizations
• Broad commercial experience spanning many therapeutic areas
• Biotech builder with biologic experience
• Extensive launch experience and builder of new therapeutic markets
• DBV Technologies, AMAG, TEVA, Schering-Plough

Bob Atwill, MBA

Bob Atwill, MBA

Head of Asia-Pacific Region and Business Development

• Over 30 years of executive pharma, biotech, cell therapy and healthcare experience
• Corporate Officer in listed NYSE, NASDAQ, LSE, ASX and in other organisations for over 23-years
• Expertise in COVID-19, GvHD, virology, I/O and cell & gene therapy
• GSK, Sanofi-Synthélabo, Mesoblast and Benitec Biopharma
• APAC based cross-border M&A and capital service principal with Eaton Square

Ken Trbovich

Ken Trbovich

SVP, Investor Relations

• 20 years on Wall Street as an equity analyst primarily covering biopharmaceutical companies
• Research coverage included companies across multiple sectors and therapeutic areas
• Analyzed more than 100 companies and published more than 2,000 reports
• Royal Bank of Canada, Janney Montgomery Scott, C.E. Unterberg, Towbin (now part of Canaccord Genuity), and MLV & Co. (now part of B. Riley)

 

BOARD OF DIRECTORS